U.S. Markets close in 2 hrs 2 mins

Chimerix, Inc. (CMRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
8.08-0.09 (-1.10%)
As of 1:53PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close8.17
Open8.24
Bid8.08 x 1000
Ask8.11 x 1300
Day's Range7.96 - 8.36
52 Week Range1.37 - 11.57
Volume144,812
Avg. Volume1,302,676
Market Cap692.288M
Beta (5Y Monthly)1.64
PE Ratio (TTM)N/A
EPS (TTM)-0.70
Earnings DateMay 05, 2021 - May 10, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.00
  • Chimerix Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2021
    GlobeNewswire

    Chimerix Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2021

    DURHAM, N.C., April 08, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced upcoming poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021, which will be held virtually from April 10-15, 2021 and May 17-21, 2021. Details for the poster presentations are as follows: ONC201: Characterization and combinatorial efficacy in brain tumors Title: ADME and toxicology profiles of first-in-class DRD2/ClpP-targeted imipridone ONC201Abstract Number: 1370Date and Time: April 10, 2021 from 8:30 a.m. - 11:59 p.m. EDT Presenter: Sara Morrow, M.S., ChimerixSession Title: Pharmacology, Pharmacogenetics, and Pharmacogenomics Title: Response to novel imipridone combination therapies targeting H3K27M mutant diffuse midline glioma (DMG)Abstract Number: 635Date and Time: April 10, 2021 from 8:30 a.m. - 11:59 p.m. EDT Presenter: Robyn Borsuk, M.D., Warren Alpert Medical School, Brown UniversitySession Title: Pediatric Cancer: Clinical Investigations Title: The integrated stress response (ISR) is involved in the synergistic combinatorial efficacy of ONC201 and epigenetic modulators in brain tumor cell linesAbstract Number: 1156Date and Time: April 10, 2021 from 8:30 a.m. - 11:59 p.m. EDT Presenter: Yiqun Zhang, Ph.D., Warren Alpert Medical School, Brown UniversitySession Title: HDAC and Methyltransferase Inhibitors ONC201: Combinatorial efficacy in other solid tumors Title: Combinatorial therapy of imipridones and histone deacetylase inhibitors in Ewing sarcoma cell lines demonstrates synergistic cell deathAbstract Number: 1060Date and Time: April 10, 2021 from 8:30 a.m. - 11:59 p.m. EDT Presenter: Wen-I Chang, M.D., Warren Alpert Medical School, Brown UniversitySession Title: Combination Therapies Title: ONC201 as a novel anti-cancer therapeutic via modulation of inhibitors of apoptosis and up-regulation of DR5 in gastric adenocarcinomaAbstract Number: 1044Date and Time: April 10, 2021 from 8:30 a.m. - 11:59 p.m. EDT Presenter: Cassandra Parker, M.D., Warren Alpert Medical School, Brown UniversitySession Title: Combination Therapies Title: Imipridones exhibit synergy with sorafenib, HDAC inhibition, PARP inhibition, and proteasome inhibition in liver cancer cell linesAbstract Number: 1040Date and Time: April 10, 2021 from 8:30 a.m. - 11:59 p.m. EDT Presenter: Joshua Honeyman, M.D., Warren Alpert Medical School, Brown UniversitySession Title: Combination Therapies ONC206: Mechanism of action and biomarkers Title: Predictive Biomarker Evaluation and Molecular Differentiation for Imipridones ONC201 and ONC206Abstract Number: 393Date and Time: April 10, 2021 from 8:30 a.m. - 11:59 p.m. EDT Presenter: Varun V. Prabhu, Ph.D., ChimerixSession Title: Biomarkers Predictive of Therapeutic Benefit Title: Novel imipridone ONC206 suppresses ovarian cancer progression through modulating immune cell responseAbstract Number: 1440Date and Time: April 10, 2021 from 8:30 a.m. - 11:59 p.m. EDT Presenter: Chi-Lam Au-Yeung, Ph.D., MD Anderson Cancer CenterSession Title: Role of Microenvironment in therapeutic response ONC212: Efficacy in pancreatic cancer Title: Combination therapy with MEK inhibitors and a novel anti-neoplastic drug, imipridone ONC212, demonstrates synergy in pancreatic ductal adenocarcinoma cell linesAbstract Number: 1006Date and Time: April 10, 2021 from 8:30 a.m. - 11:59 p.m. EDT Presenter: Alexander G. Raufi, M.D., Warren Alpert Medical School, Brown UniversitySession Title: Cellular Responses to Anticancer Drugs Title: ONC212-induced impairment of oxidative phosphorylation is synergistic with glycolysis inhibition in treatment of pancreatic cancer in vitro and in vivoAbstract Number: 2329Date and Time: April 10, 2021 from 8:30 a.m. - 11:59 p.m. EDT Presenter: Anna Louie, M.D., Warren Alpert Medical School, Brown UniversitySession Title: Metabolic Pathways Posters will be available for registered attendees on the AACR website on April 10, 2021. About Chimerix Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases. Our three most advanced clinical-stage development programs are BCV, ONC201 and DSTAT. BCV is an antiviral drug candidate developed as a potential medical countermeasure for smallpox and is currently under review for regulatory approval in the United States. ONC201 is currently in a registrational clinical program for recurrent H3 K27M-mutant glioma and a confirmatory response rate assessment is expected later this year. DSTAT is in development as a potential first-line therapy in acute myeloid leukemia and as a potential treatment for acute lung injury in hospitalized COVID-19 patients. CONTACT:Investor Relations: Michelle LaSpaluto919 972-7115ir@chimerix.com Will O’ConnorStern Investor Relations212-362-1200will@sternir.com

  • Chimerix to Present at Virtual H.C. Wainwright Global Life Sciences Conference
    GlobeNewswire

    Chimerix to Present at Virtual H.C. Wainwright Global Life Sciences Conference

    DURHAM, N.C., March 02, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman, Chief Executive Officer, will participate in a pre-recorded presentation at the H.C. Wainwright Global Life Sciences Conference made available on Tuesday, March 9, 2021 at 7:00 a.m. ET. An audio webcast of the presentation will be available on the Investor Relations section of Chimerix's website at ir.chimerix.com, where it will be archived for approximately 90 days. About Chimerix Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases. Our three most advanced clinical-stage development programs are BCV, ONC201 and DSTAT. BCV is an antiviral drug candidate developed as a potential medical countermeasure for smallpox and is currently under review for regulatory approval in the United States. ONC201 is currently in a registrational clinical program for recurrent H3 K27M-mutant glioma and a confirmatory response rate assessment is expected later this year. DSTAT is in development as a potential first-line therapy in acute myeloid leukemia and as a potential treatment for acute lung injury in hospitalized COVID-19 patients. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include those relating to, among other things, Chimerix’s ability to obtain regulatory approval for BCV; the timing and receipt of a potential procurement contract for BCV in smallpox; and the timing of enrollment in the DSTAT trial for AML. Among the factors and risks that could cause actual results to differ materially from those indicated in the forward-looking statements are risks that BCV may not obtain regulatory approval from the FDA or such approval may be delayed or conditioned; risks that Chimerix will not obtain a procurement contract for BCV in smallpox in a timely manner or at all; risks related to the timing and conduct of the DSTAT trials for AML and COVID; risks that ongoing or future trials may not be successful or replicate previous trial results, or may not be predictive of real-world results or of results in subsequent trials; risks and uncertainties relating to competitive products and technological changes that may limit demand for our drugs; risks that our drugs may be precluded from commercialization by the proprietary rights of third parties; and additional risks set forth in the Company's filings with the Securities and Exchange Commission. These forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. CONTACT:Investor Relations: Michelle LaSpaluto919 972-7115ir@chimerix.comWill O’ConnorStern Investor Relations212-362-1200will@sternir.com